RAD51 and XRCC3 Polymorphisms Are Associated with Increased Risk of Prostate Cancer.

Maria Nowacka-Zawisza,Magdalena Bryś,Agata Raszkiewicz,Tomasz Kwasiborski,Ewa Forma,Waldemar Różański,Wanda M Krajewska

doi:10.1155/2019/2976373

Maria Nowacka-Zawisza, Magdalena Bryś + Show 5 more

Open Access

https://doi.org/10.1155/2019/2976373

Copy DOI

Abstract

Genetic polymorphisms in DNA repair genes may affect DNA repair efficiency and may contribute to the risk of developing cancer. The aim of our study was to investigate single nucleotide polymorphisms (SNPs) in RAD51 (rs2619679, rs2928140, and rs5030789) and XRCC3 (rs1799796) involved in DNA double-strand break repair and their relationship to prostate cancer. The study group included 99 men diagnosed with prostate cancer and 205 cancer-free controls. SNP genotyping was performed using the PCR-RFLP method. A significant association was detected between RAD51 rs5030789 polymorphism and XRCC3 rs1799796 polymorphism and an increased risk of prostate cancer. Our results indicate that RAD51 and XRCC3 polymorphism may contribute to prostate cancer.

Highlights

Prostate cancer is the second most commonly occurring cancer and the fifth leading cause of cancer death in men with an estimated 1.3 million new cases and 359.000 associated deaths worldwide in 2018
Significant differences were found in the distribution of genotypes and alleles for rs5030789 and rs1799796 polymorphism in RAD51 and XRCC3, respectively, between control group and prostate cancer patients
The odds ratio (OR) analysis showed that rs5030789 polymorphism in RAD51 and rs1799796 polymorphism in XRCC3 are associated with susceptibility to prostate cancer (Table 4)

Summary

Introduction

Prostate cancer is the second most commonly occurring cancer and the fifth leading cause of cancer death in men with an estimated 1.3 million new cases and 359.000 associated deaths worldwide in 2018. Pathogenic variants of high and moderate penetrance genes, such as BRCA1 and BRCA2, mismatch repair genes, and HOXB13 confer modest to high lifetime risk of prostate cancer. Some, such as BRCA2, have emerging clinical relevance in the treatment and screening for prostate cancer [5,6,7,8]

Objectives

Methods

Results

Discussion

Conclusion